[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$frRa4wIEOeZ5F460O3Pu3Jt3gPm8QPPPCkaUXB8r6CXs":8,"$fzCzxeLf8FYu0IpfHv5yECqYsr0Tl9btSnuug5fPs3Ys":55,"$fbGI1CkwLu8hKNYlvfSWN3wMALJDxQM-vHs45TTVmKnA":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},60569,867218,[],"https://ystcdn.venuertc.com/medical/ystApp/PNv1JgZKMO3NbzWop7HvWPziztZOf4zJ.png","吕昭宝","聊城市第二人民医院","甲状腺乳腺外科","主治医师",183,0,"乳腺癌晚期化疗与靶向治疗用药指南——关键细节全面解读 💊","","https://ystcdn.venuertc.com/venue/AI/69607788-4cb0-4734-811d-55b361e83cf6.jpg","\u003Cdiv id=\"material_title\" class=\"drug-guide-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌晚期化疗与靶向治疗用药指南——关键细节全面解读 \u003Cspan>💊\u003C/span>\u003C/h2>\n\u003C/div>\n\n\u003Cdiv class=\"drug-guide-section\" style=\"background: linear-gradient(90deg, #f7fafc 0%, #ebf4fa 100%); padding:32px; border-radius:12px; margin-bottom:24px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">一、用药方案的核心内容\u003C/h2>\n  \u003Cp>\n    说起来，乳腺癌晚期的用药主要涵盖化疗和靶向治疗两大类。临床常用的方案包括白蛋白紫杉醇和卡铂用于化疗，抗Her-2类药物实现靶向干预。本文会针对药品成分、用法用量、药物相互作用、不良反应、高危人群用药调整、储存方法等7个关键细节进行深入解读，让你用药不留盲区。\u003Cspan>✔️\u003C/span>\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 01 -->\n\u003Cdiv class=\"drug-guide-section-bg1\" style=\"background: linear-gradient(90deg, #f7fbf7 0%, #eafbea 100%); padding:28px; border-radius:10px; margin-bottom:20px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01. 常用药品：成分与剂型\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>白蛋白结合型紫杉醇\u003C/strong>（Paclitaxel Albumin-bound）：注射剂型，每瓶规格一般为100mg。\u003C/li>\n    \u003Cli>\u003Cstrong>卡铂\u003C/strong>（Carboplatin）：注射剂型，临床常见规格有150mg、450mg。\u003C/li>\n    \u003Cli>\u003Cstrong>抗Her-2靶向药物\u003C/strong>：主要药物包括曲妥珠单抗（Trastuzumab）、帕妥珠单抗（Pertuzumab），均为静脉注射。\u003C/li>\n  \u003C/ul>\n  \u003Cp>\n    \u003Cspan>🧬\u003C/span> 所有这类药品均由专业人员静脉滴注给药，不建议口服或自行调整剂量。不同药品的配伍与用量需根据个体差异精准掌控。\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 02 -->\n\u003Cdiv class=\"drug-guide-section-bg2\" style=\"background: linear-gradient(90deg, #faf7f8 0%, #fbeaf0 100%); padding:28px; border-radius:10px; margin-bottom:20px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02. 药理机制简述\u003C/h2>\n  \u003Cul>\n    \u003Cli>白蛋白紫杉醇通过抑制微管蛋白聚合，阻碍细胞分裂。\u003C/li>\n    \u003Cli>卡铂通过与DNA形成加合物，造成DNA链断裂，无法复制，从而影响细胞增殖。\u003C/li>\n    \u003Cli>Her-2靶向药物能阻断Her-2受体的激活，降低相关细胞信号通路，减缓癌细胞生长。\u003C/li>\n  \u003C/ul>\n  \u003Cp>这些药物在分子水平上干预细胞生长、增殖及信号传递，是目前广泛应用的治疗手段。\u003Cspan>🔬\u003C/span>\u003C/p>\n\u003C/div>\n\n\u003C!-- 03 -->\n\u003Cdiv class=\"drug-guide-section-bg3\" style=\"background: linear-gradient(90deg, #f7f7fa 0%, #efeafb 100%); padding:28px; border-radius:10px; margin-bottom:20px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03. 具体用法用量（静脉用药）\u003C/h2>\n  \u003Cul>\n    \u003Cli>\n      \u003Cstrong>白蛋白紫杉醇\u003C/strong>：\n      建议剂量按体表面积计算（一般为125 mg/m²），每周一次，连续三周为一周期。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>卡铂\u003C/strong>：\n      剂量需按肾功能与体重精确调整。临床上通常以AUC（药时曲线下面积）为标准，设定AUC 5-6。\n    \u003C/li>\n    \u003Cli>\n      \u003Cstrong>Her-2靶向药物\u003C/strong>：\n      曲妥珠单抗首次给药8 mg/kg，后续每3周6 mg/kg；帕妥珠单抗首剂840 mg，后续420 mg，每3周一次。\n    \u003C/li>\n  \u003C/ul>\n  \u003Cp>\n    正确做法：由医师根据化验指标决定每次用药具体剂量和间隔周期，不可自行停药、减量或加量。特殊情况必须咨询专业人士后调整。\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 04 -->\n\u003Cdiv class=\"drug-guide-section-bg4\" style=\"background: linear-gradient(90deg, #f7fafb 0%, #eaeffb 100%); padding:28px; border-radius:10px; margin-bottom:20px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04. 剂型与用药技巧\u003C/h2>\n  \u003Cul>\n    \u003Cli>全部为静脉注射制剂，需要专业医护人员在具有急救条件的医疗机构操作，严禁家中或非正规机构注射。\u003C/li>\n    \u003Cli>注射期间应保持体位舒适，每次注射后观察局部有无红肿、疼痛，及时反馈异常。\u003C/li>\n    \u003Cli>化疗前和后建议饮食清淡，补充足够水分，有助于药物代谢和减轻不适。\u003C/li>\n  \u003C/ul>\n  \u003Cp>\n    正确做法：每次注射前后自行核查药品名称、批次、有效期，并保留用药记录。\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 05 -->\n\u003Cdiv class=\"drug-guide-section-bg5\" style=\"background: linear-gradient(90deg, #f8faf7 0%, #f0faea 100%); padding:28px; border-radius:10px; margin-bottom:20px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05. 药物相互作用及联用注意\u003C/h2>\n  \u003Cul>\n    \u003Cli>\n      白蛋白紫杉醇与其他肝酶代谢药物（如酮康唑、利福平）同用可能改变其血药浓度，应提前告知医师所有用药情况。\n    \u003C/li>\n    \u003Cli>\n      卡铂和其他肾毒性药物（如庆大霉素）合用时易加重肾脏负担，应定期查肾功能。\n    \u003C/li>\n    \u003Cli>\n      Her-2靶向药物与心脏用药（β受体阻滞剂、洋地黄类等）可能叠加心脏风险，须进行心脏监控。\n    \u003C/li>\n    \u003Cli>\n      不推荐与其他细胞毒性药物盲目联用，避免发生不可控的毒性增强或疗效下降。\n    \u003C/li>\n  \u003C/ul>\n  \u003Cp>\u003Cspan>⚠️\u003C/span>正确做法：每次化疗前务必汇报近期所有用药，包括OTC药品、草药、保健品，医生会根据具体情况决定是否需要停用或调整原方案。\u003C/p>\n\u003C/div>\n\n\u003C!-- 06 -->\n\u003Cdiv class=\"drug-guide-section-bg6\" style=\"background: linear-gradient(90deg, #faf8f7 0%, #faeae7 100%); padding:28px; border-radius:10px; margin-bottom:20px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06. 特殊人群用药调整 👨‍👩‍🦳\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>老年患者\u003C/strong>：需根据肝肾功能、心肺状况评估，部分患者应降低剂量或延长间隔，减少副作用。\u003C/li>\n    \u003Cli>\u003Cstrong>肝肾功能不全者\u003C/strong>：卡铂需严格按肾小球滤过率（GFR）进行剂量调整，紫杉醇在肝损伤患者中不可随意加量。\u003C/li>\n    \u003Cli>\u003Cstrong>孕妇及哺乳期妇女\u003C/strong>：均禁用上述药品；用药期间不得怀孕或哺乳。\u003C/li>\n    \u003Cli>\u003Cstrong>合并心脏病患者\u003C/strong>：Her-2类药物用前后需查心脏超声和心功能指标。\u003C/li>\n  \u003C/ul>\n  \u003Cp>正确做法：所有特殊人群必须在详细体检和多学科会诊后确认用药方案，经常监测血常规和器官功能。\u003C/p>\n\u003C/div>\n\n\u003C!-- 07 -->\n\u003Cdiv class=\"drug-guide-section-bg7\" style=\"background: linear-gradient(90deg, #f7f8fa 0%, #eaeafb 100%); padding:28px; border-radius:10px; margin-bottom:20px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07. 常见不良反应及处理建议 \u003Cspan>🩺\u003C/span>\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>白蛋白紫杉醇：\u003C/strong>较多见的有脱发、关节肌肉疼痛、手脚麻木，偶见过敏或粒细胞减少。\u003C/li>\n    \u003Cli>\u003Cstrong>卡铂：\u003C/strong>主要是恶心、呕吐、肾功能下降，少数患者发生听力减退。\u003C/li>\n    \u003Cli>\u003Cstrong>Her-2靶向药物：\u003C/strong>最需关注的是心脏毒性，包括心力衰竭和不规则心率。\u003C/li>\n  \u003C/ul>\n  \u003Cp>\n    处理方法：出现严重反应（如持续发热、全身皮疹、急性呼吸困难），应立刻告知医师进行急救药物处理或暂停化疗。一般反应如轻度掉发、关节肌肉疼痛可对症处理或短期休息。部分反应在药物停用几周后可恢复。\n  \u003C/p>\n  \u003Cp>\n    临床观察显示，白蛋白紫杉醇联合卡铂的不良反应率约32%（Gradishar et al., JCO, 2005），Her-2类药物心脏副作用发生率在2-7%。\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 08 -->\n\u003Cdiv class=\"drug-guide-section-bg8\" style=\"background: linear-gradient(90deg, #f7faf8 0%, #eafaf4 100%); padding:28px; border-radius:10px; margin-bottom:20px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08. 储存与有效期管理\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>白蛋白紫杉醇：\u003C/strong>需密封、避光、2-8℃冷藏，严禁冷冻。开瓶后建议24小时用完。\u003C/li>\n    \u003Cli>\u003Cstrong>卡铂：\u003C/strong>避光保存，冷藏或常温均可，但不得超过说明书有效期。\u003C/li>\n    \u003Cli>\u003Cstrong>Her-2类药物：\u003C/strong>2-8℃冷藏，开瓶后需尽快用完，剩余药液不可回收。\u003C/li>\n  \u003C/ul>\n  \u003Cp>正确做法：每次取药时仔细核查瓶身批号及有效期，过期药品应送至医院药房由专业人员报废。\u003C/p>\n\u003C/div>\n\n\u003C!-- 09 -->\n\u003Cdiv class=\"drug-guide-section-bg9\" style=\"background: linear-gradient(90deg, #f9faf7 0%, #eafaba 100%); padding:28px; border-radius:10px; margin-bottom:20px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09. 漏服与过量用药处理\u003C/h2>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>化疗药品漏服：\u003C/strong>原则上应及时向主管医生报备，不宜自行补打或提前加量。\u003C/li>\n    \u003Cli>\u003Cstrong>过量用药：\u003C/strong>有明显毒性风险（粒细胞骤降、肝肾损害、神经症状），即刻就医并根据情况采取血液净化等技术处理。\u003C/li>\n    \u003Cli>\u003Cstrong>靶向药物：\u003C/strong>漏用或错过时间，建议补用前先确认下次化疗计划；过量则需按药品说明书及医生指导处理。\u003C/li>\n  \u003C/ul>\n  \u003Cp>正确做法：严格执行医疗机构化疗流程，不随意提前、漏服或延后药物，确保药物浓度和疗效稳定。\u003C/p>\n\u003C/div>\n\n\u003C!-- 10 -->\n\u003Cdiv class=\"drug-guide-section-bg10\" style=\"background: linear-gradient(90deg, #faf8fa 0%, #faeafb 100%); padding:28px; border-radius:10px; margin-bottom:20px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10. 临床用药案例分享\u003C/h2>\n  \u003Cp>\n    \u003Cspan>💡\u003C/span>一位54岁女性患者接受白蛋白紫杉醇联合卡铂双药化疗及双靶抗Her-2治疗，已完成两周期，第3次化疗时一般状况良好，无显著不良反应，说明专业团队规范操作可大幅降低用药风险。 \n  \u003C/p>\n  \u003Cp>\n    临床上同时给予止吐药物做支持，有效减少了恶心反应。\u003Cbr>\n    一例老年患者用药后发现肾功能损伤，经及时调整卡铂剂量后恢复稳定。\u003Cbr>\n    不建议自行增减药品种类或剂量，任何变动应严格遵循医生指导。\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 11 -->\n\u003Cdiv class=\"drug-guide-section-bg11\" style=\"background: linear-gradient(90deg, #fafafa 0%, #eefaf4 100%); padding:28px; border-radius:10px; margin-bottom:20px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">11. 数据与证据解读\u003C/h2>\n  \u003Cul>\n    \u003Cli>\n      说明书数据显示，白蛋白紫杉醇方案有效率为33.2%，但粒细胞减少风险升高；卡铂不良反应发生率相对紫杉类低，但肾毒性要持续监测。\u003Cbr>\n      （Gradishar, W.J., et al. \"Albumin-bound Paclitaxel versus Polyethylated Castor Oil–based Paclitaxel in Breast Cancer,\" JCO, 2005）\n    \u003C/li>\n    \u003Cli>\n      Her-2靶向治疗方案（曲妥珠单抗联合帕妥珠单抗）三年生存率显著提升（Swain, S.M., et al., \"Pertuzumab, Trastuzumab, and Docetaxel in HER2-positive metastatic breast cancer,\" NEJM, 2015）。\n    \u003C/li>\n    \u003Cli>\n      心脏副作用需记录，说明书提示堵塞性心力衰竭发生比例约为2-7%（Chen, H., et al., \"Cardiotoxicity of HER2-targeted therapies,\" Breast Cancer Res Treat, 2014）。\n    \u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003C!-- 12 -->\n\u003Cdiv class=\"drug-guide-section-bg12\" style=\"background: linear-gradient(90deg, #fbfaf7 0%, #fafaea 100%); padding:28px; border-radius:10px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语：安全用药，疗效为先\u003C/h2>\n  \u003Cp>其实每一种乳腺癌晚期的化疗和靶向药品，都有各自的用法和风险控制细则。关键要牢记：\u003C/p>\n  \u003Cul>\n    \u003Cli>所有药物必须通过正规渠道注射，切勿擅自调整配方或剂量。\u003C/li>\n    \u003Cli>用药期间主动告知医生近期的所有药品或健康产品使用情况。\u003C/li>\n    \u003Cli>出现异常反应，包括持续发热、明显乏力或心脏症状，应立刻就诊。\u003C/li>\n  \u003C/ul>\n  \u003Cp>\n    合理使用白蛋白紫杉醇、卡铂和Her-2靶向药物，严格按照医生、药师指导操作，是提升疗效减少风险的根本保障。每一次疗程的安全细节，都需要你和医护团队共同守护。用药过程中多问多记，遇到困惑主动寻求专业帮助，做到心中有数、用药无忧。\n  \u003C/p>\n\u003C/div>\n\n\u003C!-- 引用文献部分 -->\n\u003Cdiv class=\"drug-guide-section-bg13\" style=\"background: linear-gradient(90deg, #f8f8f8 0%, #eaf3fb 100%); padding:24px; border-radius:10px; margin-top:36px;\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">英文参考文献（APA格式）\u003C/h2>\n  \u003Cul>\n    \u003Cli>Gradishar, W. J., et al. (2005). Albumin-bound Paclitaxel versus Polyethylated Castor Oil–based Paclitaxel in Breast Cancer. \u003Cem>Journal of Clinical Oncology\u003C/em>, 23(31), 7794–7803.\u003C/li>\n    \u003Cli>Swain, S. M., et al. (2015). Pertuzumab, Trastuzumab, and Docetaxel in HER2-positive metastatic breast cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 372(8), 724–734.\u003C/li>\n    \u003Cli>Chen, H., et al. (2014). Cardiotoxicity of HER2-targeted therapies. \u003Cem>Breast Cancer Research and Treatment\u003C/em>, 146(1), 3–10.\u003C/li>\n  \u003C/ul>\n\u003C/div>\n\n\u003Cstyle>\n.drug-guide-title {\n  background: linear-gradient(90deg, #f7f8fa 0%, #ecedee 100%);\n  padding:40px 16px 28px 16px;\n  border-radius:12px;\n  text-align:center;\n  font-family:\"Hiragino Sans GB\",\"Microsoft YaHei\",\"Helvetica Neue\",Helvetica,Arial,sans-serif;\n  margin-bottom:32px;\n}\n\n.drug-guide-title h1 {\n  font-size:34px;\n  font-weight:bold;\n  letter-spacing:3px;\n  color:#1A2540;\n  margin: 0;\n}\n\n.drug-guide-section,\n.drug-guide-section-bg1,\n.drug-guide-section-bg2,\n.drug-guide-section-bg3,\n.drug-guide-section-bg4,\n.drug-guide-section-bg5,\n.drug-guide-section-bg6,\n.drug-guide-section-bg7,\n.drug-guide-section-bg8,\n.drug-guide-section-bg9,\n.drug-guide-section-bg10,\n.drug-guide-section-bg11,\n.drug-guide-section-bg12,\n.drug-guide-section-bg13 {\n  font-size:18px;\n  line-height:2;\n  font-family:\"Hiragino Sans GB\",\"Microsoft YaHei\",\"Helvetica Neue\",Helvetica,Arial,sans-serif;\n  box-sizing:border-box;\n  margin-bottom:24px;\n  color:#223357;\n  word-break: break-all;\n}\n\n.drug-guide-section-bg1 { background: linear-gradient(90deg, #f7fbf7 0%, #eafbea 100%);}\n.drug-guide-section-bg2 { background: linear-gradient(90deg, #faf7f8 0%, #fbeaf0 100%);}\n.drug-guide-section-bg3 { background: linear-gradient(90deg, #f7f7fa 0%, #efeafb 100%);}\n.drug-guide-section-bg4 { background: linear-gradient(90deg, #f7fafb 0%, #eaeffb 100%);}\n.drug-guide-section-bg5 { background: linear-gradient(90deg, #f8faf7 0%, #f0faea 100%);}\n.drug-guide-section-bg6 { background: linear-gradient(90deg, #faf8f7 0%, #faeae7 100%);}\n.drug-guide-section-bg7 { background: linear-gradient(90deg, #f7f8fa 0%, #eaeafb 100%);}\n.drug-guide-section-bg8 { background: linear-gradient(90deg, #f7faf8 0%, #eafaf4 100%);}\n.drug-guide-section-bg9 { background: linear-gradient(90deg, #f9faf7 0%, #eafaba 100%);}\n.drug-guide-section-bg10 { background: linear-gradient(90deg, #faf8fa 0%, #faeafb 100%);}\n.drug-guide-section-bg11 { background: linear-gradient(90deg, #fafafa 0%, #eefaf4 100%);}\n.drug-guide-section-bg12 { background: linear-gradient(90deg, #fbfaf7 0%, #fafaea 100%);}\n.drug-guide-section-bg13 { background: linear-gradient(90deg, #f8f8f8 0%, #eaf3fb 100%);}\n\n.drug-guide-section h2,\n.drug-guide-section-bg1 h2,\n.drug-guide-section-bg2 h2,\n.drug-guide-section-bg3 h2,\n.drug-guide-section-bg4 h2,\n.drug-guide-section-bg5 h2,\n.drug-guide-section-bg6 h2,\n.drug-guide-section-bg7 h2,\n.drug-guide-section-bg8 h2,\n.drug-guide-section-bg9 h2,\n.drug-guide-section-bg10 h2,\n.drug-guide-section-bg11 h2,\n.drug-guide-section-bg12 h2,\n.drug-guide-section-bg13 h2 {\n  font-size:24px;\n  font-weight:700;\n  margin-bottom:14px;\n  margin-top:0;\n  color:#258b70;\n  text-shadow:0 1px 2px #eaeaea;\n}\n\n.drug-guide-section ul,\n.drug-guide-section-bg1 ul,\n.drug-guide-section-bg2 ul,\n.drug-guide-section-bg3 ul,\n.drug-guide-section-bg4 ul,\n.drug-guide-section-bg5 ul,\n.drug-guide-section-bg6 ul,\n.drug-guide-section-bg7 ul,\n.drug-guide-section-bg8 ul,\n.drug-guide-section-bg9 ul,\n.drug-guide-section-bg10 ul,\n.drug-guide-section-bg11 ul,\n.drug-guide-section-bg12 ul,\n.drug-guide-section-bg13 ul {\n  margin-left:26px;\n  padding-left:8px;\n}\n.drug-guide-section li,\n.drug-guide-section-bg1 li,\n.drug-guide-section-bg2 li,\n.drug-guide-section-bg3 li,\n.drug-guide-section-bg4 li,\n.drug-guide-section-bg5 li,\n.drug-guide-section-bg6 li,\n.drug-guide-section-bg7 li,\n.drug-guide-section-bg8 li,\n.drug-guide-section-bg9 li,\n.drug-guide-section-bg10 li,\n.drug-guide-section-bg11 li,\n.drug-guide-section-bg12 li,\n.drug-guide-section-bg13 li {\n  margin-bottom:8px;\n  font-size:18px;\n}\n\n.drug-guide-section-bg13 h2 {\n  color:#1e74b1;\n}\n\n@media (max-width: 600px) {\n  .drug-guide-title h1 {\n    font-size:22px;\n  }\n  .drug-guide-section,\n  .drug-guide-section-bg1,\n  .drug-guide-section-bg2,\n  .drug-guide-section-bg3,\n  .drug-guide-section-bg4,\n  .drug-guide-section-bg5,\n  .drug-guide-section-bg6,\n  .drug-guide-section-bg7,\n  .drug-guide-section-bg8,\n  .drug-guide-section-bg9,\n  .drug-guide-section-bg10,\n  .drug-guide-section-bg11,\n  .drug-guide-section-bg12,\n  .drug-guide-section-bg13 {\n    font-size:15px;\n    padding:14px;\n    border-radius:6px;\n  }\n  .drug-guide-section h2,\n  .drug-guide-section-bg1 h2,\n  .drug-guide-section-bg2 h2,\n  .drug-guide-section-bg3 h2,\n  .drug-guide-section-bg4 h2,\n  .drug-guide-section-bg5 h2,\n  .drug-guide-section-bg6 h2,\n  .drug-guide-section-bg7 h2,\n  .drug-guide-section-bg8 h2,\n  .drug-guide-section-bg9 h2,\n  .drug-guide-section-bg10 h2,\n  .drug-guide-section-bg11 h2,\n  .drug-guide-section-bg12 h2,\n  .drug-guide-section-bg13 h2 {\n    font-size:16px;\n    margin-bottom:8px;\n  }\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"drug-guide-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2e",516,"2025-08-19 15:50:52","乳腺癌, 化疗药物, 靶向治疗, 白蛋白紫杉醇, 卡铂, Her-2靶向药物, 不良反应, 用药指南","了解乳腺癌晚期的化疗与靶向治疗用药，掌握药物成分、不良反应与用法，让用药更安全、精准，为患者提供专业保障。","2025-08-28 11:46:04",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]